Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.

Prior to the 2025 American Heart Association (AHA) Scientific Sessions Meeting, Craig J. Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, discusses two recent papers that are influencing practice within the cardiovascular space.

This video explores the evolving treatment landscape for ROS1-positive non-small cell lung cancer (NSCLC), focusing on targeted therapies, clinical evidence for repotrectinib, management of adverse events, and the pharmacist’s role in improving patient care and adherence.

Craig Beavers discusses recent developments in hypertension management and the clinical implications of the Bax Hypertension and KARDIA-3 trials with Shelby Tungate from the UNC Eshelman School of Pharmacy.

William Van Decker, MD, discusses the key priorities of the upcoming ACC Legislative Conference, including telehealth, cardiovascular rehab, prior authorization reform, and the role of pharmacists in shaping patient-centered cardiovascular policy.

Host Craig Beavers discusses the validity of meta-analyses and highlights analyses from European Society of Cardiology (ESC) 2025 with Bill Baker, PharmD, FCCP, FACC, FAHA.

Host Craig Beavers sits down with Lorenz van der Linden, a Belgian pharmacist, to dive deep into 2 groundbreaking trials from the European Society of Cardiology (ESC) 2025 Congress.

Experts discuss radon—the second leading cause of lung cancer.